Results 91 to 100 of about 26,895 (263)

SGLT2 inhibitor use and renal outcomes in low-risk population with diabetes mellitus and normal or low body mass index

BMJ Open Diabetes Research & Care
Introduction Recent post hoc analyses indicate that patients with normal or low body mass index (BMI) benefit from sodium-glucose cotransporter-2 (SGLT2) inhibitor use. We aimed to evaluate the effects of SGLT2 inhibitors on renal and patient outcomes in
Hye Ryoun Jang, Jung Eun Lee, Wooseong Huh, Yun Soo Lee, Goeun Park, Kyungho Lee, Junseok Jeon   +6 more
doaj   +1 more source

Sodium‐glucose cotransporter 2 inhibitors and the risk of late onset epilepsy: A real‐world cohort study

Epilepsia, EarlyView.
Abstract Objective Late onset epilepsy (LOE) is associated with substantial morbidity. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) may exert neuroprotective effects. This study evaluated the association between SGLT2i and risk of LOE among older adults with type 2 diabetes mellitus.
Bing‐Hua Lin, Hui‐Min Huang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Short‐term clinical responses in horses and ponies treated with canagliflozin: A clinical field study

Equine Veterinary Journal, EarlyView.
Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom, Sanna Truelsen Lindåse, Monika Wartel, Johan Bröjer   +3 more
wiley   +1 more source

Food‐grade proteins, lipids, and fibers as potential tools to ameliorate cardiovascular disorders: A review

Food Biomacromolecules, EarlyView.
Abstract Cardiovascular diseases (CVDs) remain the leading cause of global mortality, necessitating effective preventive and adjunct therapeutic strategies beyond conventional pharmacological interventions. Although previous reviews have focused on individual nutrients or dietary patterns, this review provides a mechanism‐based, integrative perspective
Sridevi Shanmugam, Rukaiah Fatma Begum, Nirenjen Shanmugasundaram, Bhupendra Gopalbhai Prajapati, Suresh Ankul Singh, Pavithra Nagenthran, Sudarshan Singh, Kesarla Rajesh   +7 more
wiley   +1 more source

A Systematic Review and Expert Evaluation of Perioperative SGLT2 Inhibitor-Associated Ketoacidosis Case Reports. [PDF]

Acta Anaesthesiol Scand
ABSTRACT Introduction The use of sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in the perioperative setting may lead to SGLT2i‐associated postoperative ketoacidosis (SAPKA) in patients with type 2 diabetes (T2D). Therefore, cessation of this drug is recommended before surgery.
Snel LIP, Li X, Jamaludin F, Siegelaar SE, Holleman F, Vriesendorp TM, DeVries JH, Hoekstra JBL, Preckel B, van Raalte DH, Hermanides J, Hulst AH.   +11 more
europepmc   +2 more sources

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source

Prevalence Rate of Adverse Drug Reactions from Sodium-Glucose Cotransporter-2 Inhibitors: A Retrospective Cohort Study

Pharmacoepidemiology
Background/Objectives: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are widely used in type 2 diabetes mellitus for glycemic control and cardiovascular–renal protection, but adverse effects such as acute kidney injury (AKI), urinary tract infection (
Pichitra Srimaya, Tossapol Warong, Sudarat Kingdang, Titawadee Pradubkham, Wiraphol Phimarn   +4 more
doaj   +1 more source

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

iNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little, Stefan Offermanns, Haaglim Cho, Zhiping Liu, Pinglian Yang, Qiaozhu Su, Henry Wade, Wah Yang, Danielle Kamato, Neale Cohen, Alex Bobik, Iqra Ilyas, Suowen Xu   +12 more
wiley   +1 more source

SGLT2 inhibitors: expanding their Empire beyond diabetes [PDF]

The Lancet Diabetes & Endocrinology, 2021
Muskiet, Marcel H. A., Heerspink, Hiddo J. L., van Raalte, Daniel H.   +2 more
openaire   +2 more sources

Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities

ESC Heart Failure, Volume 12, Issue 2, Page 723-726, April 2025.
Stephan von Haehling
wiley   +1 more source